| The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms JD Khoury, E Solary, O Abla, Y Akkari, R Alaggio, JF Apperley, R Bejar, ... leukemia 36 (7), 1703-1719, 2022 | 1675 | 2022 |
| A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma N Korde, M Carlsten, MJ Lee, A Minter, E Tan, M Kwok, E Manasanch, ... Haematologica 99 (6), e81, 2014 | 134 | 2014 |
| Distinguishing hairy cell leukemia variant from hairy cell leukemia: development and validation of diagnostic criteria H Shao, KR Calvo, M Grönborg, PR Tembhare, RJ Kreitman, ... Leukemia research 37 (4), 401-409, 2013 | 134 | 2013 |
| Modeling progression risk for smoldering multiple myeloma: results from a prospective clinical study BM Cherry, N Korde, M Kwok, EE Manasanch, M Bhutani, M Mulquin, ... Leukemia & lymphoma 54 (10), 2215-2218, 2013 | 113 | 2013 |
| Flow cytometric differentiation of abnormal and normal plasma cells in the bone marrow in patients with multiple myeloma and its precursor diseases PR Tembhare, CM Yuan, D Venzon, R Braylan, N Korde, E Manasanch, ... Leukemia research 38 (3), 371-376, 2014 | 102 | 2014 |
| Clinical impact of panel-based error-corrected next generation sequencing versus flow cytometry to detect measurable residual disease (MRD) in acute myeloid leukemia (AML) N Patkar, C Kakirde, AF Shaikh, R Salve, P Bhanshe, G Chatterjee, ... Leukemia 35 (5), 1392-1404, 2021 | 63 | 2021 |
| Evaluation of new markers for minimal residual disease monitoring in B‐cell precursor acute lymphoblastic leukemia: CD73 and CD86 are the most relevant new markers to increase … PR Tembhare, S Ghogale, N Ghatwai, Y Badrinath, N Kunder, NV Patkar, ... Cytometry Part B: Clinical Cytometry 94 (1), 100-111, 2018 | 59 | 2018 |
| A high‐sensitivity 10‐color flow cytometric minimal residual disease assay in B‐lymphoblastic leukemia/lymphoma can easily achieve the sensitivity of 2‐in‐106 and is superior … PR Tembhare, PG Subramanian PG, S Ghogale, G Chatterjee, NV Patkar, ... Cytometry Part B: Clinical Cytometry 98 (1), 57-67, 2020 | 58 | 2020 |
| Flow Cytometric Immunophenotypic Assessment of T-Cell Clonality by Vβ Repertoire Analysis: Detection of T-Cell Clonality at Diagnosis and Monitoring of Minimal … P Tembhare, CM Yuan, L Xi, JC Morris, D Liewehr, D Venzon, JE Janik, ... American journal of clinical pathology 135 (6), 890-900, 2011 | 52 | 2011 |
| Diagnosis of hairy cell leukemia by flow cytometry M Stetler-Stevenson, PR Tembhare Leukemia & lymphoma 52 (sup2), 11-13, 2011 | 39 | 2011 |
| Population pharmacokinetics of Reditux™, a biosimilar Rituximab, in diffuse large B-cell lymphoma V Gota, A Karanam, S Rath, A Yadav, P Tembhare, P Subramanian, ... Cancer chemotherapy and pharmacology 78, 353-359, 2016 | 36 | 2016 |
| Flow cytometric evaluation of CD38 expression levels in the newly diagnosed T-cell acute lymphoblastic leukemia and the effect of chemotherapy on its expression in measurable … PR Tembhare, H Sriram, T Khanka, G Chatterjee, D Panda, S Ghogale, ... Journal for Immunotherapy of Cancer 8 (1), 2020 | 35 | 2020 |
| A novel and easy F xCycle™ violet based flow cytometric method for simultaneous assessment of DNA ploidy and six‐color immunophenotyping P Tembhare, Y Badrinath, S Ghogale, N Patkar, N Dhole, P Dalavi, ... Cytometry Part A 89 (3), 281-291, 2016 | 34 | 2016 |
| Clinical impact of measurable residual disease monitoring by ultradeep next generation sequencing in NPM1 mutated acute myeloid leukemia N Patkar, R Kodgule, C Kakirde, G Raval, P Bhanshe, S Joshi, ... Oncotarget 9 (93), 36613, 2018 | 33 | 2018 |
| Phase II clinical and correlative study of carfilzomib, lenalidomide, and dexamethasone (CRd) in newly diagnosed multiple myeloma (MM) patients N Korde, A Zingone, M Kwok, EE Manasanch, R Costello, D Zuchlinski, ... Blood 120 (21), 732, 2012 | 30 | 2012 |
| Flow Cytometric Immunophenotypic Assessment of T-Cell Clonality by Vβ Repertoire Analysis in Fine-Needle Aspirates and Cerebrospinal Fluid P Tembhare, CM Yuan, JC Morris, JE Janik, AC Filie, M Stetler-Stevenson American journal of clinical pathology 137 (2), 220-226, 2012 | 26 | 2012 |
| Outcomes and prognostic factors in adolescents and young adults with ALL treated with a modified BFM-90 protocol A Rajendra, H Jain, VNA Bonda, L Nayak, P Tembhare, D Shetty, J Thorat, ... Blood advances 5 (5), 1178-1193, 2021 | 25 | 2021 |
| Infection prevalence in adolescents and adults with acute myeloid leukemia treated in an Indian tertiary care center H Jain, K Rengaraj, V Sharma, A Bonda, R Chanana, J Thorat, A Ronghe, ... JCO Global Oncology 6, 1684-1695, 2020 | 24 | 2020 |
| MYD88 mutant lymphoplasmacytic lymphoma/Waldenström macroglobulinemia has distinct clinical and pathological features as compared to its mutation negative counterpart N Patkar, PG Subramanian, P Deshpande, K Ghodke, P Tembhare, ... Leukemia & lymphoma 56 (2), 420-425, 2015 | 24 | 2015 |
| Characteristics of BCR-ABL kinase domain mutations in chronic myeloid leukemia from India: not just missense mutations but insertions and deletions are also … N Patkar, K Ghodke, S Joshi, S Chaudhary, R Mascerhenas, S Dusseja, ... Leukemia & lymphoma 57 (11), 2653-2660, 2016 | 22 | 2016 |
